JP2022058682A5 - - Google Patents

Download PDF

Info

Publication number
JP2022058682A5
JP2022058682A5 JP2022007043A JP2022007043A JP2022058682A5 JP 2022058682 A5 JP2022058682 A5 JP 2022058682A5 JP 2022007043 A JP2022007043 A JP 2022007043A JP 2022007043 A JP2022007043 A JP 2022007043A JP 2022058682 A5 JP2022058682 A5 JP 2022058682A5
Authority
JP
Japan
Prior art keywords
synergistic combination
gram
composition
amino acid
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022007043A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022058682A (ja
Filing date
Publication date
Priority claimed from JP2019221319A external-priority patent/JP2020054370A/ja
Application filed filed Critical
Publication of JP2022058682A publication Critical patent/JP2022058682A/ja
Publication of JP2022058682A5 publication Critical patent/JP2022058682A5/ja
Pending legal-status Critical Current

Links

JP2022007043A 2012-05-09 2022-01-20 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ Pending JP2022058682A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261644944P 2012-05-09 2012-05-09
US61/644,944 2012-05-09
US201261737239P 2012-12-14 2012-12-14
US61/737,239 2012-12-14
JP2019221319A JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019221319A Division JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Publications (2)

Publication Number Publication Date
JP2022058682A JP2022058682A (ja) 2022-04-12
JP2022058682A5 true JP2022058682A5 (https=) 2023-01-04

Family

ID=49551273

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015511698A Expired - Fee Related JP6608697B2 (ja) 2012-05-09 2013-05-09 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2018086685A Withdrawn JP2018138045A (ja) 2012-05-09 2018-04-27 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2019221319A Pending JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2022007043A Pending JP2022058682A (ja) 2012-05-09 2022-01-20 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2015511698A Expired - Fee Related JP6608697B2 (ja) 2012-05-09 2013-05-09 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2018086685A Withdrawn JP2018138045A (ja) 2012-05-09 2018-04-27 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ
JP2019221319A Pending JP2020054370A (ja) 2012-05-09 2019-12-06 グラム陽性菌に対するバクテリオファージ溶解素と抗生物質との組み合わせ

Country Status (16)

Country Link
US (5) US10813983B2 (https=)
EP (2) EP2849782B1 (https=)
JP (4) JP6608697B2 (https=)
KR (3) KR102310387B1 (https=)
CN (1) CN104736172A (https=)
AU (3) AU2013259512B2 (https=)
BR (1) BR112014027842A2 (https=)
CA (1) CA2872902A1 (https=)
DK (1) DK2849782T3 (https=)
ES (1) ES2784136T3 (https=)
HK (1) HK1211484A1 (https=)
IL (3) IL308477A (https=)
IN (1) IN2014MN02437A (https=)
MX (2) MX389127B (https=)
RU (2) RU2018121290A (https=)
WO (1) WO2013170015A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
BR112014027818B1 (pt) 2012-05-09 2023-03-28 Contrafect Corporation Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano
WO2015200783A2 (en) * 2014-06-26 2015-12-30 The Rockefeller University Acinetobacter lysins
WO2016142445A2 (en) * 2015-03-12 2016-09-15 Micreos Human Health B.V. A method of treatment of a bacterial infection
EP4115897A1 (en) * 2015-09-17 2023-01-11 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
EP3454888B1 (en) * 2016-05-12 2021-02-24 Contrafect Corporation Broth microdilution method for evaluating and determining minimal inhibitory concentration of antibacterial polypeptides
CA3067542A1 (en) 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
US20220023399A1 (en) * 2017-07-10 2022-01-27 Contrafect Corporation Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
BR112020017219A2 (pt) * 2018-02-26 2020-12-22 Contrafect Corporation Lisinas plyss2 modificadas e usos das mesmas
BR112020026267A2 (pt) * 2018-06-22 2021-04-06 Contrafect Corporation Lisinas e seus derivados resensibilizam novamente staphylococcus aureus e bactérias gram-positivas aos antibióticos
CN109668873B (zh) * 2018-12-05 2021-03-16 山东恒业生物技术有限公司 一种活载体疫苗活性检测装置及其使用方法
MX2021009389A (es) 2019-02-05 2021-11-17 Elanco Us Inc Lactobacillus modificado geneticamente y usos del mismo.
JP2022525914A (ja) * 2019-03-22 2022-05-20 コントラフェクト コーポレイション 感染性心内膜炎を治療する方法
WO2020210691A1 (en) * 2019-04-11 2020-10-15 Contrafect Corporation Method of treating and preventing bone and joint infections
CN119837855A (zh) * 2019-12-19 2025-04-18 乔治亚州大学研究基金会 用于治疗细菌感染和增强抗生素的化合物
US20230277632A1 (en) * 2020-05-19 2023-09-07 Contrafect Corporation MODIFIED PlySs2 LYSINS AND ANTIBIOTIC COMBINATIONS FOR USE AGAINST GRAM-POSITIVE BACTERIA
RU2755817C1 (ru) * 2020-07-22 2021-09-21 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Способ снижения грамположительной микрофлоры в кишечнике птицы
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
WO2022261360A1 (en) * 2021-06-09 2022-12-15 Contrafect Corporation Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria
CN115105491B (zh) * 2022-07-08 2023-12-22 东北农业大学 丝氨酸在制备抑制猪链球菌药物中的用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
CA1315229C (en) 1987-06-10 1993-03-30 Eli Lilly And Company Chromatographic purification process
EP0895534A1 (en) * 1996-04-15 1999-02-10 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US6248324B1 (en) 1997-10-31 2001-06-19 Vincent Fischetti Bacterial phage associated lysing enzymes for treating dermatological infections
US6264945B1 (en) 1997-10-31 2001-07-24 Vincent A Fischetti Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US6254866B1 (en) 1997-10-31 2001-07-03 New Horizons Diagnostics Corporation Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
US5997862A (en) 1997-10-31 1999-12-07 New Horizons Diagnostics Corporation Therapeutic treatment of group A streptococcal infections
US20060292135A1 (en) 1997-10-31 2006-12-28 Lawrence Loomis Use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl
AU2876799A (en) 1999-02-25 2000-09-14 New Horizons Diagnostics, Inc. A means for the prophylactic and therapeutic treatment of streptococcal infections
US6056955A (en) 1999-09-14 2000-05-02 Fischetti; Vincent Topical treatment of streptococcal infections
US6444813B2 (en) 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
JP2006513149A (ja) 2002-05-17 2006-04-20 ニュー ホライゾンズ ディアグノスティックス コーポレイション Ｂａｃｉｌｌｕｓａｎｔｈｒａｃｉｓを迅速かつ特異的に検出および殺滅するファージ関連溶菌酵素の同定
US7569223B2 (en) 2004-03-22 2009-08-04 The Rockefeller University Phage-associated lytic enzymes for treatment of Streptococcus pneumoniae and related conditions
EP1744779A2 (en) * 2004-03-24 2007-01-24 The Rockfeller University Lytic enzymes and spore surface antigen for detection and treatment of "bacillus anthracis" bacteria and spores
US8389469B2 (en) 2005-06-06 2013-03-05 The Rockefeller University Bacteriophage lysins for Bacillus anthracis
US7582291B2 (en) 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
EP2360248A1 (en) 2005-08-24 2011-08-24 The Rockefeller University Ply-GBS mutant lysins
WO2009029192A1 (en) 2007-08-24 2009-03-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Surfactant-based antimicrobial solution for inhalation
WO2010002959A2 (en) * 2008-07-03 2010-01-07 The Rockefeller University A chimeric bacteriophage lysin with activity against staphylococci bacteria
KR101016918B1 (ko) 2009-01-08 2011-02-25 주식회사 인트론바이오테크놀로지 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질
EP2539446B1 (en) 2010-01-25 2017-11-01 Alere Scarborough Inc. A25 bacteriophage lysin
US20120271770A1 (en) * 2011-04-20 2012-10-25 Visa International Service Association Managing electronic tokens in a transaction processing system
EP2699689A4 (en) 2011-04-21 2014-12-17 Univ Utrecht Holding Bv STREPTOCOCCUS BACTERIOPHAGEN LYSINE FOR THE TREATMENT OF GRAM-POSITIVE BACTERIA IN PETS AND UTILITIES
DK2699253T3 (en) 2011-04-21 2018-07-16 Univ Rockefeller STREPTOCOCCUS BACTERYPHAGIC LYSINES FOR THE DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIES
WO2012145693A1 (en) 2011-04-22 2012-10-26 Rks Design, Inc. Instrument retention assembly
EP2702070B1 (en) 2011-04-27 2015-09-30 Lysando AG New antimicrobial agents
BR112014027818B1 (pt) 2012-05-09 2023-03-28 Contrafect Corporation Usos de composições compreendendo polipeptídeo de lisina para prevenção, ruptura ou tratamento de um biofilme bacteriano
RU2018121290A (ru) 2012-05-09 2019-03-06 Контрафект Корпорейшн Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий

Similar Documents

Publication Publication Date Title
JP2022058682A5 (https=)
RU2020133461A (ru) Предотвращение, разрушение и обработка биопленки лизином бактериофага
RU2014149351A (ru) Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий
Tagg Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius
Eckmann et al. Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
Feld Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons
Plouffe Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid
Finney et al. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections
JP2014518849A5 (https=)
RU2018107249A (ru) Применение лизина для восстановления/увеличения антибактериальной активности антибиотиков в присутствии легочного сурфактанта, который ингибирует указанные антибиотики
HRP20131170T1 (hr) Nova antibakterijska sredstva za lijeäśenje gram-pozitivnih infekcija
Paterson Clinical experience with recently approved antibiotics
Fan et al. Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria
Oksuz et al. Susceptibility of clinical methicillin-resistant Staphylococci isolates to new antibiotics
Chaftari et al. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients
JP2021513865A5 (https=)
RU2020128276A (ru) МОДИФИЦИРОВАННЫЕ ЛИЗИНЫ PlySs2 И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
RU2020127327A (ru) Патогенные бактерии
RU2004118716A (ru) Лечение инфекции, вызываемой микроорганизмами
Kajihara et al. Comparative efficacies of daptomycin, vancomycin, and linezolid in experimental enterococcal peritonitis
Bell et al. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008)
Suh Resolution of persistent Pediococcus bacteremia with daptomycin treatment: case report and review of the literature
Fiore et al. The possible role of anti-methicillin-resistant Staphylococcus aureus antimicrobial agents in spontaneous bacterial peritonitis
WO2010131865A3 (ko) 항생제 내성 균주에 대한 항균용 조성물
Leone et al. Severe bacterial infections in haemodialysis patients